Abstract: Aspects of the invention include methods of removing carbon dioxide (CO2) from a CO2 containing gas. In some instances, the methods include contacting CO2 containing gas with a bicarbonate buffered aqueous medium under conditions sufficient to produce a bicarbonate rich product. Where desired, the resultant bicarbonate rich product or a component thereof may then be stored or further processed, e.g., combined with a divalent alkaline earth metal cation, under conditions sufficient to produce a solid carbonate composition. Aspects of the invention further include systems for practicing the methods, as well as products produced by the methods.

Abstract: There is provided a sensor fiber including an electrically insulating material having a fiber length. At least one transduction element is disposed along at least a portion of the fiber length and is arranged for exposure to an intake species. A photoconducting element is in optical communication with the transduction element. At least one pair of electrically conducting electrodes are in electrical connection with the photoconducting element. The pair of electrodes extend the fiber length.

Abstract: The present invention relates to methods of treating hepatitis C infection, HIV infection, AIDS, or AIDS-related complex, or inhibiting HIV replication by administering a compound of Formula I wherein: X is H or OH; Y is H or OH; R1 is H or halogen (F, Cl, Br, I); R2 is H or halogen (F, Cl, Br, I); R3 is H, C1-6 alkyl, C1-6 fluoroalkyl, or benzyl; R4 is H, C1-6 alkyl, or benzyl; and R5 is H or C1-6 alkyl; or pharmaceutically acceptable salts thereof, to a mammal.

Abstract: A method for secure transmission of a message encrypted under an attribute based encryption scheme is provided. A first and a second authority parameter may be received from one or more authorities. A policy is generated based on the parameters. The generated policy comprises a flexible access control structure. A ciphertext is constructed based on the policy. To decrypt the ciphertext, key components are received from one or more authorities, the key components associated with a decryptor identifier. A decryption key is generated based on the policy and the key components. A plaintext is generated by decrypting the ciphertext.

Abstract: The present invention provides HIV protease inhibitors of formulas I, IA, IB, Ib or II, or pharmaceutically acceptable salts thereof, wherein R2 may be, for example, 2-pyridyl-CH2—, 3 -pyridyl-CH2—, 4-pyridyl-CH2—, a sulfonyl group as described in the formulas herein including benzenesulfonyl or thiophenesulfonyl groups, R2a—CO—, R2a being selected from the group consisting of piperonyl, 2-pyrazinyl (unsubstituted or substituted with H, or an alkyl of 1 to 4 carbon atoms) or a picolylamine group as described herein, wherein R3 may be, for example, a phenyl group or diphenylmethyl group as described herein, and wherein Cx may be, for example, COOH, CONR5R6, CH2OH or CH2OR7.

Abstract: The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I inhibit HIV-integrase enzyme and are useful for preventing and treating of HIV infection and AIDS.

Abstract: A method for secure transmission of a message encrypted under an attribute based encryption scheme is provided. A first and a second authority parameter may be received from one or more authorities. A policy is generated based on the parameters. The generated policy comprises a flexible access control structure. A ciphertext is constructed based on the policy. To decrypt the ciphertext, key components are received from one or more authorities, the key components associated with a decryptor identifier. A decryption key is generated based on the policy and the key components. A plaintext is generated by decrypting the ciphertext.

Abstract: The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I inhibit HIV-integrase enzyme and are useful for preventing and treating of HIV infection, acquired immune deficiency syndrome (AIDS), AIDS-related complex (ARC), hepatitis C, and other diseases and conditions caused or mediated by HIV infection.

Abstract: The present invention provides methods for improving the pharmacokinetics of protease inhibitors and protease inhibitor precursors and pharmaceutical composition comprising protease inhibitors or protease inhibitor precursors of formula I and a cytochrome P450 monooxigenase inhibitor; when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.

Abstract: The present invention provides lysine based compounds of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.

Abstract: The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I inhibit HIV-integrase enzyme and are useful for preventing and treating of HIV infection and AIDS.

Abstract: The present invention provides HIV protease inhibitors of formulas I, IA, IB, Ib or II, or pharmaceutically acceptable salts thereof, wherein R2 may be, for example, 2-pyridyl-CH2—, 3-pyridyl-CH2—, 4-pyridyl-CH2—, a sulfonyl group as described in the formulas herein including benzenesulfonyl or thiophenesulfonyl groups, R2a—CO)—, R2a being selected from the group consisting of piperonyl, 2-pyranzinyl (unsubstituted or substituted with H, or an alkyl of 1 to 4 carbon atoms) or a picolylamine group as described herein, wherein R3 may be, for example, a phenyl group or diphenylmethyl group as described herein, and wherein Cx may be, for example, COOH, CONR5R6, CH2OH or CH2OR7.

Abstract: The present invention provides processes for synthesizing lysine based compounds of the formula; , wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, wherein X may be, for example, NH2, Y may be H, F, Cl, or Br, and wherein n, X?, Y?, R2, R3, R4, R5 and R6 are as defined herein.

Abstract: A mapping method for converting objects in order to optimize utilization of a programming environment on an associated platform includes the steps of identifying a strongly typed object and a type of conversion. A name of a weakly typed object is based upon an attribute associated with a target object and reflection is used on the strongly typed object to obtain properties of the object input parameter. Default names are assigned and stored based upon the obtained properties in a dictionary cache. The dictionary cache is used to complete attributes associated with new object for use in the programming environment.

Abstract: The present invention provides lysine based compounds of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.

Abstract: The present invention provides lysine based compounds of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.

Abstract: The tire deflation device (30) includes a rail member (34) having a support portion (38) and a piercing portion (44). The piercing portion (44) of the rail member (34) extends toward a tire (20) and is located between the tire (20) and a protected portion (44) of the automotive vehicle (10). The piercing portion (44) is intended to puncture and deflate the tire (20) when a crush zone (18) is deformed inwardly so as to force the tire (20) into the piercing portion (44) of the rail member (34). The support portion (38) has at least one anchor member (32) fixedly attached thereto for securely mounting the rail member (34) to a side mount (12) of the automotive vehicle (10) within a middle rigid zone (14) thereof.

Abstract: The tire deflation device (30) includes a rail member (34) having a support portion (38) and a piercing portion (40). The piercing portion (40) of the rail member (34) extends toward a tire (20) and is located between the tire (20) and a protected portion (40) of the automotive vehicle (10). The piercing portion (40) is intended to puncture and deflate the tire (20) when a crush zone (18) is deformed inwardly so as to force the tire (20) into the piercing portion (40) of the rail member (34). The support portion (38) has at least one anchor member (32) fixedly attached thereto for securely mounting the rail member (34) to a side mount (12) of the automotive vehicle (10) within a middle rigid zone (14) thereof.

Abstract: A compound selected from the group consisting of a compound of formula I a compound of formula II and when the compound of formula I and II comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein R1, R2, Cx, n, R3, R4, R5, Y are as defined in the specification.

Abstract: A compound selected from the group consisting of a compound of formula I a compound of formula II and when the compound of formula I and II comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein R1, R2, Cx, n, R3, R4, R5, Y are as defined in the specification.